Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sabina Cevoli

Showing results (121-130 of 142) with videos related to

Pageof 15
Sort By:
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 7, 2023
Gender-related stress factors and emotional perception in migraine: a structured online questionnaire in migraine patients and controlsMarianna Delussi, Giulia Piraino, Simona Guerzoni, et al.
Journal of Neurology|June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experienceClaudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
Cephalalgia : an International Journal of Headache|April 26, 2022
Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot studyPierangelo Geppetti, Francesco De Cesaris, Silvia Benemei, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
The Journal of Headache and Pain|January 6, 2025
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, et al.
The Journal of Headache and Pain|February 15, 2019
Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraineSimona Sacco, Silvia Benemei, Sabina Cevoli, et al.
Journal of Neurology|January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology|April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Therapeutic Advances in Neurological Disorders|December 25, 2025
Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study)Gloria Vaghi, Luigi Francesco Iannone, Michele Corrado, et al.
Pageof 15

Showing results (121-130 of 142) with videos related to

Sort By:
Pageof 15
The Journal of Headache and Pain|May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 7, 2023
Gender-related stress factors and emotional perception in migraine: a structured online questionnaire in migraine patients and controlsMarianna Delussi, Giulia Piraino, Simona Guerzoni, et al.
Journal of Neurology|June 28, 2022
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experienceClaudia Altamura, Nicoletta Brunelli, Marilena Marcosano, et al.
Cephalalgia : an International Journal of Headache|April 26, 2022
Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot studyPierangelo Geppetti, Francesco De Cesaris, Silvia Benemei, et al.
European Journal of Neurology|November 26, 2021
Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life studyFabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
The Journal of Headache and Pain|January 6, 2025
Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, et al.
The Journal of Headache and Pain|February 15, 2019
Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraineSimona Sacco, Silvia Benemei, Sabina Cevoli, et al.
Journal of Neurology|January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology|April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational studyPiero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Therapeutic Advances in Neurological Disorders|December 25, 2025
Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study)Gloria Vaghi, Luigi Francesco Iannone, Michele Corrado, et al.
Pageof 15